Hydralazine Dosing for Acute Severe Hypertension in Pregnancy
For acute severe hypertension in pregnancy (BP ≥160/110 mmHg), administer hydralazine 5 or 10 mg intravenously as a slow bolus, repeated every 20 minutes as needed, up to a maximum of 5 doses (total 50 mg), with treatment initiated within 60 minutes of the first severe BP reading. 1
Dosing Protocol
The standard hydralazine regimen consists of:
- Initial dose: 5 or 10 mg IV as a slow bolus 1, 2
- Repeat dosing: Every 20 minutes if target BP not achieved 3
- Maximum: 5 doses total 1, 3
- Target BP: ≤140/90 mmHg or reduction to non-severe range (<160/110 mmHg) 1
The FDA label specifies the usual dose range as 20-40 mg repeated as necessary, though obstetric guidelines favor the lower 5-10 mg incremental approach 2. Blood pressure should be checked every 10 minutes during treatment, with maximal effect typically occurring 10-80 minutes after injection 2.
Critical Timing Requirements
Treatment must be initiated within 60 minutes of the first severe BP reading (≥160 systolic OR ≥110 diastolic), not from the second confirmatory reading 1. This represents a quality metric with ideal performance of 100% compliance. Severe hypertension is defined as a single measurement meeting these thresholds—waiting for confirmation delays potentially life-saving treatment.
Administration Considerations
Route and Preparation
- Administer as direct IV bolus injection into the vein 2
- Use immediately after opening the vial—do not add to infusion solutions 2
- Discard any discolored solutions (hydralazine may discolor upon metal contact) 2
- Avoid continuous IV infusion: A study of continuous hydralazine infusion (starting at 5 mg/hr, titrated up) resulted in fetal distress requiring cesarean delivery in 5 of 7 patients due to rapid, uncontrolled BP decline 4
Expected Response
Hydralazine achieves BP control faster than labetalol (mean 50 minutes vs. 75 minutes) and requires fewer doses (mean 1.85 vs. 3.68 doses) 5. However, it produces more variable individual responses in terms of peak effects and duration 6.
Safety Profile and Monitoring
Maternal Side Effects
Common adverse effects include:
- Tachycardia and palpitations (significantly more frequent than with labetalol, p=0.01 and p=0.05 respectively) 3
- Headache
- Maternal hypotension (rare—only 2/100 patients in one trial) 3
Fetal Considerations
While hydralazine has been used extensively in pregnancy without evidence of teratogenicity in humans, the FDA label notes animal studies showed teratogenic effects at high doses 2. In clinical practice, neonatal hypotension and bradycardia occur less frequently with hydralazine than labetalol 3.
Critical Pitfall
Excessive BP reduction can compromise cerebral perfusion. Avoid reducing MAP by more than 25% or dropping SBP by more than 80 mmHg, as this exceeds cerebral autoregulatory limits 7. In patients with increased intracranial pressure, lowering BP may paradoxically increase cerebral ischemia 2.
Comparative Efficacy
Hydralazine is one of three first-line agents for acute severe hypertension in pregnancy, alongside labetalol IV and nifedipine immediate-release oral 1. Research shows:
- Labetalol achieves target BP in 83.8% vs. hydralazine 71.2% (p=0.007), suggesting better overall efficacy 5
- Oral nifedipine may be more effective than either IV agent, achieving target BP in 100% of patients in one pilot study 8
- Both hydralazine and labetalol are equally effective with similar safety profiles in head-to-head trials 9, 3
When to Transition
Most patients can be transitioned to oral antihypertensive therapy within 24-48 hours 2. For ongoing BP management during pregnancy, first-line oral agents include extended-release nifedipine and labetalol 10.